OCLI Vision Breaks New Ground with ENCELTO Therapy for MacTel OCLI Vision, part of Spectrum Vision Partners, has successfully performed the first ENCELTO gene therapy for treating MacTel, offering hope to patients.

OCLI Vision Breaks New Ground with ENCELTO Therapy for MacTel #USA #Garden_City #Encelto #OCLI_Vision #MacTel

ENCELTO Implant Slows Vision Loss in MacTel Phase III trials confirm ENCELTO’s neuroprotective implant slows vision loss in macular telangiectasia type 2 (MacTel).

🚨 BREAKTHROUGH for vision loss: The FDA just approved Encelto, the first-ever treatment for Macular Telangiectasia type 2 (MacTel) - a living implant that protects vision from inside the eye. #Encelto #MacTel #MedTech buff.ly/9Le7LSv

ENCELTO Implant Protects Against Vision-Destroying Eye Disease - Drugs.com MedNews MONDAY, Aug. 11, 2025 A newly approved implant appears to slow vision loss from a rare and previously untreatable eye disease, researchers report. The eye impla

FDA approves #ENCELTO - first treatment for rare MacTel eye disease. Tiny implant reduced vision loss by 31-55% in trials. "Instead of waiting for cells to die, we're protecting them," researcher says. Hope for 0.1% affected worldwide! 👁️ www.drugs.com/news/encelto...

Recent FDA Approvals Highlight Innovations in Treatment Options The FDA has recently approved groundbreaking treatments, enhancing options for patients with rare diseases and severe allergies in children.

Recent FDA Approvals Highlight Innovations in Treatment Options #United_States #FDA #Silver_Spring #Encelto #Neffy